Trial Profile
A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 19 Sep 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Mocetinostat (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors NYU Langone Medical Center
- 19 Sep 2022 Results assessing clinical and immune correlate results were published in the Melanoma Research.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 19 May 2020 Status changed from recruiting to discontinued.